08:18 AM EST, 11/14/2025 (MT Newswires) -- Anavex Life Sciences ( AVXL ) shares were down more than 43% on Friday after a European regulator informed the company of a negative trend vote on its marketing authorization application for blarcamesine treating early Alzheimer's disease.
Anavex said it plans to request a re-examination of the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency on the application after it adopts a formal opinion on the application in December.
The company said it plans to provide relevant biomarker data, based on feedback from the agencies and the Alzheimer's disease community.